1
|
Mercer TR, Dinger ME and Mattick JS: Long
non-coding RNAs: Insights into functions. Nat Rev Genet.
10:155–159. 2009. View
Article : Google Scholar : PubMed/NCBI
|
2
|
Redis RS, Vela LE, Lu W, Ferreira de
Oliveira J, Ivan C, Rodriguez-Aguayo C, Adamoski D, Pasculli B,
Taguchi A, Chen Y, et al: Allele-specific reprogramming of cancer
metabolism by the long non-coding RNA CCAT2. Mol Cell. 61:6402016.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Mercer TR and Mattick JS: Structure and
function of long noncoding RNAs in epigenetic regulation. Nat
Struct Mol Biol. 20:300–307. 2013. View Article : Google Scholar : PubMed/NCBI
|
4
|
Huppi K, Pitt JJ, Wahlberg BM and Caplen
NJ: The 8q24 gene desert: An Oasis of non-coding transcriptional
activity. Front Genet. 3:692012. View Article : Google Scholar : PubMed/NCBI
|
5
|
Grisanzio C and Feedman ML: Chromosome
8q24-associated cancers and MYC. Genes Cancer. 1:555–559. 2010.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Xiang JF, Yang L and Chen LL: The long
noncoding RNA regulation at the MYC locus. Curr Opin Genet Dev.
33:41–48. 2015. View Article : Google Scholar : PubMed/NCBI
|
7
|
Huang S, Qing C, Huang Z and Zhu Y: The
long non-coding RNA CCAT2 is up-regulated in ovarian cancer and
associated with poor prognosis. Diagn Pathol. 11:492016. View Article : Google Scholar : PubMed/NCBI
|
8
|
Zhao X, Wei X, Zhao L, Shi L, Cheng J,
Kang S, Zhang H, Zhang J, Li L, Zhang H and Zhao W: The rs6983267
SNP and long non-coding RNA CARLo-5 are associated with endometrial
carcinoma. Environ Mol Mutagen. 57:508–515. 2016. View Article : Google Scholar : PubMed/NCBI
|
9
|
Kim T, Cui R, Jeon YJ, Lee JH, Lee JH, Sim
H, Park JK, Fadda P, Tili E, Nakanishi H, et al: Long-range
interaction and correlation between MYC enhancer and oncogenic long
noncoding RNA CARLo-5. Proc Natl Acad Sci USA. 111:4173–4178. 2014.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Han J, Zhou J, Yuan H, Zhu L, Ma H, Hang D
and Li D: Genetic variants within the cancer susceptibility region
8q24 and ovarian cancer risk in Han Chinese women. Oncotarget.
8:36462–36468. 2017. View Article : Google Scholar : PubMed/NCBI
|
11
|
Hua F, Li CH, Chen XG and Liu XP: Long
noncoding RNA CCAT2 knockdown suppresses tumorous progression by
sponging miR-424 in epithelial ovarian cancer. Oncol Res.
26:241–247. 2018. View Article : Google Scholar : PubMed/NCBI
|
12
|
Ghoussaini M, Song H, Koessler T, Al Olama
AA, Kote-Jarai Z, Driver KE, Pooley KA, Ramus SJ, Kjaer SK, Hogdall
E, et al: Multiple loci with different cancer specificities within
the 8q24 gene desert. J Natl Cancer Inst. 100:962–966. 2008.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Barry KH, Moore LE, Sampson J, Yan L,
Meyer A, Oler AJ, Chung CC, Wang Z, Yeager M, Amundadottir L and
Berndt SI: DNA methylation levels at chromosome 8q24 in peripheral
blood are associated with 8q24 cancer susceptibility loci. Cancer
Prev Res (Phila). 7:1282–1292. 2014. View Article : Google Scholar : PubMed/NCBI
|
15
|
Sotelo J, Esposito D, Duhagon MA, Banfield
K, Mehalko J, Liao H, Stephens RM, Harris TJ, Munroe DJ and Wu X:
Long-range enhancers on 8q24 regulate c-Myc. Proc Natl Acad Sci
USA. 107:3001–3005. 2010. View Article : Google Scholar : PubMed/NCBI
|
16
|
Newtson AM, Devor EJ and Gonzalez Bosquet
J: Prediction of epithelial ovarian cancer outcomes with
integration of genomic data. Clin Obstet Gynecol. 63:92–108. 2020.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Bursac Z, Gauss CH, Williams DK and Hosmer
DW: Purposeful selection of variables in logistic regression.
Source Code Biol Med. 3:172008. View Article : Google Scholar : PubMed/NCBI
|
18
|
Reyes HD, Devor EJ, Warrier A, Newtson AM,
Mattson J, Wagner V, Duncan GN, Leslie KK and Gonzalez-Bosquet J:
Differential DNA methylation in high-grade serous ovarian cancer
(HGSOC) is associated with tumor behavior. Sci Rep. 9:179962019.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Gonzalez Bosquet J, Devor EJ, Newtson AM,
Smith BJ, Bender DP, Goodheart MJ, McDonald ME, Braun TA, Thiel KW
and Leslie KK: Creation and validation of models to predict
response to primary treatment in serous ovarian cancer. Sci Rep.
11:59572021. View Article : Google Scholar : PubMed/NCBI
|
20
|
R Core Team R, . A Language and
environment for statistical computing. 2016.http://www.R-project.org/
|
21
|
Schroder MS, Culhane AC, Quackenbush J and
Haibe-Kains B: Survcomp: An R/Bioconductor package for performance
assessment and comparison of survival models. Bioinformatics.
27:3206–3208. 2011. View Article : Google Scholar : PubMed/NCBI
|
22
|
Bolton KL, Chenevix-Trench G, Goh C,
Sadetzki S, Ramus SJ, Karlan BY, Lambrechts D, Despierre E,
Barrowdale D, McGuffog L, et al: Association between BRCA1 and
BRCA2 mutations and survival in women with invasive epithelial
ovarian cancer. JAMA. 307:382–390. 2012. View Article : Google Scholar : PubMed/NCBI
|
23
|
Vencken PMLH, Kriege M, Hoogwerf D,
Beugelink S, van der Burg MEL, Hooning MJ, Berns EM, Jager A,
Collée M, Burger CW and Seynaeve C: Chemosensitivity and outcome of
BRCA1- and BRCA2-associated ovarian cancer patients after
first-line chemotherapy compared with sporadic ovarian cancer
patients. Ann Oncol. 22:1346–1352. 2011. View Article : Google Scholar : PubMed/NCBI
|
24
|
Jiang X, Li X, Li W, Bai H and Zhang Z:
PARP inhibitors in ovarian cancer: Sensitivity prediction and
resistance mechanisms. J Cell Mol Med. 23:2303–2313. 2019.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Ledermann JA, Drew Y and Kristeleit RS:
Homologous recombination deficiency and ovarian cancer. Eur J
Cancer. 60:49–58. 2016. View Article : Google Scholar : PubMed/NCBI
|
26
|
Frey MK and Pothuri B: Homologous
recombination deficiency (HRD) testing in ovarian cancer clinical
practice: A review of the literature. Gynecol Oncol Res Pract.
4:42017. View Article : Google Scholar : PubMed/NCBI
|
27
|
Ma G, Gu D, Lv C, Chu H, Xu Z, Tong N,
Wang M, Tang C, Xu Y, Zhang Z, et al: Genetic variant in 8q24 is
associated with prognosis for gastric cancer in a Chinese
population. J Gastroenterol Hepatol. 30:689–695. 2015. View Article : Google Scholar : PubMed/NCBI
|
28
|
Shen L, Du M, Wang C, Gu D, Wang M, Zhang
Q, Zhao T, Zhang X, Tan Y, Huo X, et al: Clinical significance of
POU5F1P1 rs10505477 polymorphism in Chinese gastric cancer patients
receving cisplatin-based chemotherapy after surgical resection. Int
J Mol Sci. 15:12764–12777. 2014. View Article : Google Scholar : PubMed/NCBI
|
29
|
Hu L, Chen SH, Lv QL, Sun B, Qu Q, Qin CZ,
Fan L, Guo Y, Cheng L and Zhou HH: Clinical significance of long
non-coding RNA CASC8 rs10505477 polymorphism in lung cancer
susceptibility, platinum-based chemotherapy response, and toxicity.
Int J Environ Res Public Health. 13:5452016. View Article : Google Scholar : PubMed/NCBI
|
30
|
Gong WJ, Yin JY, Li XP, Fang C, Xiao D,
Zhang W, Zhou HH, Li X and Liu ZQ: Association of
well-characterized lung cancer lncRNA polymorphisms with lung
cancer susceptibility and platinum-based chemotherapy response.
Tumour Biol. 37:8349–8358. 2016. View Article : Google Scholar : PubMed/NCBI
|
31
|
Haerian MS, Baum L and Haerian BS:
Association of 8q24.21 loci with the risk of colorectal cancer: A
systematic review and meta-analysis. J Gastroenterol Hepatol.
26:1475–1484. 2011. View Article : Google Scholar : PubMed/NCBI
|
32
|
Wu ER, Hsieh MJ, Chiang WL, Hsueh KC, Yang
SF and Su SC: Association of lncRNA CCAT2 and CASC8 gene
polymorphisms with hepatocellular carcinoma. Int J Environ Res
Public Health. 16:28332019. View Article : Google Scholar : PubMed/NCBI
|
33
|
Tong Y, Tang Y, Li S, Zhao F, Ying J, Qu
Y, Niu X and Mu D: Cumulative evidence of relationships between
multiple variants in 8q24 region and cancer incidence. Medicine
(Baltimore). 99:e207162020. View Article : Google Scholar : PubMed/NCBI
|
34
|
Cipollini M, Figlioli G, Garritano S,
Bramante S, Maiorano L, Gnudi F, Cecchini A, De Paola F, Damicis L,
Frixa T, et al: Risk of differentiated thyroid carcinoma and
polymorphisms within the susceptibility cancer region 8q24. Cancer
Epidemiol Biomarkers Prev. 22:2121–2125. 2013. View Article : Google Scholar : PubMed/NCBI
|
35
|
Goode EL, Chenevix-Trench G, Song H, Ramus
SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson
MC, Kjaer SK, et al: A genome-wide association study identifies
susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet.
42:874–879. 2010. View
Article : Google Scholar : PubMed/NCBI
|
36
|
Pomerantz MM, Ahmadiyeh N, Jia L, Herman
P, Verzi MP, Doddapaneni H, Beckwith CA, Chan JA, Hills A, Davis M,
et al: The 8q24 cancer risk variant rs6983267 shows long-range
interaction with MYC in colorectal cancer. Nat Genet. 41:882–884.
2009. View
Article : Google Scholar : PubMed/NCBI
|
37
|
Wright JB, Brown SJ and Cole MD:
Upregulation of c-MYC in cis through a large chromatin loop linked
to a cancer risk-associated single-nucleotide polymorphism in
colorectal cancer cells. Mol Cell Biol. 30:1411–1420. 2010.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Tuupanen S, Turunen M, Lehtonen R,
Hallikas O, Vanharanta S, Kivioja T, Björklund M, Wei G, Yan J,
Niittymäki I, et al: The common colorectal cancer predisposition
SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt
signaling. Nat Genet. 41:885–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
39
|
Ahmadiyeh N, Pomerantz MM, Grisanzio C,
Herman P, Jia L, Almendro V, He HH, Brown M, Liu XS, Davis M, et
al: 8q24 prostate, breast, and colon cancer risk loci show
tissue-specific long-range interaction with MYC. Proc Natl Acad Sci
USA. 107:9742–9746. 2010. View Article : Google Scholar : PubMed/NCBI
|
40
|
Wasserman NF, Aneas I and Nobrega MA: An
8q24 gene desert variant associated with prostate cancer risk
confers differential in vivo activity to a MYC enhancer. Genome
Res. 20:1191–1197. 2010. View Article : Google Scholar : PubMed/NCBI
|
41
|
Lowe SW, Cepero E and Evan G: Intrinsic
tumour suppression. Nature. 432:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
42
|
Murphy DJ, Junttila MR, Pouyet L, Karnezis
A, Shchors K, Bui DA, Brown-Swigart L, Johnson L and Evan GI:
Distinct thresholds govern Myc's biological output in vivo. Cancer
Cell. 14:447–457. 2008. View Article : Google Scholar : PubMed/NCBI
|
43
|
Hoshimoto S, Hishinuma S, Shirakawa H,
Tomikawa M, Ozawa I and Ogata Y: Association of preoperative
Platelet-to-Lymphocyte ratio with poor outcome in patients with
distal cholangiocarcinoma. Oncology. 96:290–298. 2019. View Article : Google Scholar : PubMed/NCBI
|
44
|
Chao JS, Zhao SL, Ou-Yang SW, Qian YB, Liu
AQ, Tang HM, Zhong L, Peng ZH, Xu JM and Sun HC: Post-transplant
infection improves outcome of hepatocellular carcinoma patients
after orthotopic liver transplantation. World J Gastroenterol.
25:5630–5640. 2019. View Article : Google Scholar : PubMed/NCBI
|
45
|
Miller MD, Devor EJ, Salinas EA, Newtson
AM, Goodheart MJ, Leslie KK and Gonzalez-Bosquet J: Population
substructure has implications in validating next-generation cancer
genomics studies with TCGA. Int J Mol Sci. 20:11922019. View Article : Google Scholar : PubMed/NCBI
|